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CHLORAMBUCIL (CHL) is a biftunctioial
alkylating agent commonly used in the
treatment of advanced human cancers
(Goodman & Gilman, 1975). Althouglh
available since the late 1950s, only
recently have its metabolism (McLean et
al., 1980) and disposition kinetics been
described. Alberts et al. (1979) reported
that after oral administration CHL rapidly
appeared in the plasma and was eliminated
with a disappearance half-life of - 1 5 h.
Phenylacetic acid mustard (PAAM), the
major plasma metabolite, also appeared
rapidly in the plasma, and had a dis-
appearance half-life of 2-5 h. Because
the plasma concentration-time product
(CXT) for PAAM was 45%o larger than for
CHL, PAAM could play an important role
in the in vivo anticancer activity of CHL.
In the present stuidies we report the in
vitro anticancer activity of CHI, and its
major metabolites in a soft-agar cloning
system.
Chlorambucil was obtained frorm
Burroughs Wellcome Co. (Lot, 8B0112,
Research Triangle Park, NC). De-
hydrochloramnbucil (DCHL), 2-[4-N,N-
bis (2-chloroethyl)aminophenyl]acetic acid
(phenylacetic acid mustard, PAAM), and
2[4-N-(2-chloroetlhyl)aminophenyl]acetic
acid (monochloroethyl APAA) were syn-
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thesized, purified, crystallized, and identi-
fied by mass-spectrometry gas chromato-
graphy as described previously (McLean
et al., 1980). All compounds were dissolved
in 1000% DM8O and stored at - 80°C
until use. Immediately before testing the
solutions were thawed and diluted with
coldl 0.9%O sterile NaCl to a final DMSO
concentration of 40%. This solution was
further diluted with Hanks' balanced salt
solution (HBSS, GIBCO) to yield the
(lesired drug concentration.
Two human cell lines were used for
drug testing: the RPMI 8226 myeloma
line (IgG-lambda-chain-secreting, Ameri-
can Type Culture Collection, Rockville
MD) and the Hec IA endometrial-carci-
Inoma line (Kuramoto et al., 1972). The
cell lines were maintained in standard
media (8226:RPMI-1 640, Hec IA:McCoys
5A GIBCO) enriched with L-glutamine
(292 .tg/l00 ml), 1000 foetal calf serunm
(heat-inactivated at 57°C for 1 h, GIBCO)
and penicillin G-streptomycin (GIBCO).
Cells were harvested by centrifugation,
divided and resuspended in fresh medium
24-48 h before drug testing.
Drug sensitivity was tested in a simpli-
fied 2-layer soft-agar cloning system
(Salmon et al., 1978). The cell suspensions
were incubated with varying concentra-
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FIG. 1.-Effect of chlorambucil and its meta-
bolites on 8226 myeloma colony formation.
Each graph represents a single experiment.
Results areplotted aspercentage ofcolonies
surviving V8 drug concentration. Each
point represents the average +s.d. of 3
plates counted. 0 CHL; * PAAM;
OL DCHL; * monochloroethyl APAA.
tions of CHL or one of its metabolites at
37°C for 1 h. The cells were then washed
twice with HBSS and plated in 35mm
plastic Petri dishes. Standard medium
with 0-3% agar was used; conditioned
media or media enrichments were not
required for these cell lines. Plates were
incubated at 37°C in a humidified atmos-
phere (5% C02) until tumour colonies
reached the 30-40-cell stage (10-14 days).
Separate control plates were incubated
after exposure to HBSS or HBSS+6.6%
DMSO, the highest concentration of




FIG. 2.-Effect of chlorambucil and its meta-
bolites on Hec 1A endometrial carcinoma
colony formation. Each graph represents a
single experiment. Results are plotted as
percentage of colonies surviving V8 drug
concentration. Each point represents the
average +s.d. of 3 plates counted. Symbols
as in Fig. 1.
exposed. All control and drug assays were
plated in triplicate. Each drug assay was
duplicated.
Plating efficiencies for the 2 studies
using the 8226 cell line were 5.8% and
1.5%. Dose-response curves are shown in
Fig. 1. Because different drug concentra-
tions were used in each experiment, the
results were not averaged but are pre-
sented as 2 separate studies. Each point
represents the average of 3 plates counted
+s.d. CHL, PAAM and DCHL had
similar activities, with 70% inhibition of
colony formation at concentrations be-
tween 2 and 4 lug/ml. Monochloroethyl
APAA was less active, requiring 20 ,ug/ml
to achieve 80% inhibition ofcolony forma-
tion. Plating efficiencies for the 2 studies
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FIG. 3.-Scheme for the metabolism of
chlorambucil (McLean et al., 1980). 1,
CHL; 2, 2,3, DCHL; 3, 3,4 DCHC; 4,
PAAM; 5, Monochloroethyl APAA.
using the Hec IA cell line were 1.4% and
1.9%. This cell line required 3-8 ,ug/ml of
CHL, PAAM and DCHL to achieve 70%
inhibition of colony formation (Fig. 2).
Again, the monochloroethyl metabolite
was less active, producing 30% inhibition
of colony formation at a concentration of
20 ,g/ml.
Using an in vitro cloning system we have
shown that CHL and its 2 bifunctional
alkylating metabolites, PAAM and DCHL,
have similar inhibitory effects on CFUs of
2 neoplastic human cell lines. The mono-
functional alkylating metabolite was less
active, requiring 10-20-fold drug concen-
trations to produce comparable inhibition
of CFU.
McLean et al. (1980) have described the
metabolism of [3H] CHL in Sprague-
Dawley rats (Fig. 3). Initial metabolism
appears to be through beta oxidation of
the butyric acid side chain, leading to the
unsaturated intermediate DCHL. This
metabolic pathway is analogous to the
mitochondral beta oxidation of fatty
acids. Further oxidation to an acetic-acid
side chain leads to the major plasma meta-
bolite PAAM. Both this compound and
the dehydro intermediate (DCHL) remain
bifunctional alkylating agents, since there
has been no alteration of the N-bis(2-
chloroethyl) side chain. Further metabol-
ism cleaves one of the 2-chloroethyl side
chains yielding the major urinary meta-
bolite monochloroethyl APAA, a mono-
functional alkylating agent.
When administered orally to man, CHL
is rapidly absorbed and metabolized,
yielding high plasma concentrations of
both CHL and PAAM (Alberts et al., 1979;
McLean et al., 1979). Although there are
no significant differences in peak plasma
concentrations, the plasma half-life for
PAAM is longer than that ofCHL. Hence,
the area under the plasma disappearance
curve (CXT) for PAAM is almost 45%
greater than that of CHL. Since CHL and
PAAM have similar inhibitory effects on
turnover CFUs. PAAM may be important
intheinvivo anticanceractivityofCHL.
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